DS
DYN icon

David Shaw’s Dyne Therapeutics DYN Stock Holding History

David Shaw’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50,000
Closed -$1.42M – 4553
2024
Q1 		$1.42M Buy
+50,000
New +$1.13M ﹤0.01% 2869

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

David Shaw's DYN Position: Q2 2026 in Review

David Shaw opened a new position in Dyne Therapeutics (DYN) in Q2 2026: 60,161 shares worth $1.34M. The stake represents ﹤0.01% of the portfolio and ranks #3543 among its holdings. This is a return to the name: David Shaw previously reported a position in DYN as recently as Q3 2025.

David Shaw first reported a position in DYN in Q4 2020 and has held it in 10 quarters since. The position peaked at $4.85M in Q2 2025. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • David Shaw held 60,161 shares of Dyne Therapeutics worth $1.34M as of Q2 2026.
  • Dyne Therapeutics was a new David Shaw position in Q2 2026.
  • Dyne Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3543 holding.
  • David Shaw first reported a position in Dyne Therapeutics in Q4 2020 and has held it in 10 quarters since.
  • David Shaw's Dyne Therapeutics position peaked at $4.85M in Q2 2025.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.